Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
We are utilizing our proprietary FUSION System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to significantly improve disease treatments for the patients we serve. We aim to cure. REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Additionally, Biomea's management team will be hosting one-on-one meetings throughout the conference, taking place from January 13 to January 16.
加利福尼亞州紅木城，2025年1月6日（環球新聞通訊社）-- Biomea Fusion, Inc.（"Biomea"）（納斯達克：BMEA）是一家臨牀階段生物製藥公司，致力於發現和開發口服共價小分子，以治療和改善糖尿病、肥胖症和遺傳性癌症患者的生活。今天，Biomea宣佈首席執行官兼董事會主席托馬斯·巴特勒將在2025年1月15日（星期三）下午1:30（太平洋時間）/ 下午4:30（東部時間）舉行的第43屆年度摩根大通醫療會議上進行演講。此外，Biomea的管理團隊將在會議期間進行一對一會議，會議將於1月13日至1月16日舉行。
A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea's website at . A replay of the webcast will be available following the live presentation.
可以在此處訪問演講的直播音頻網絡廣播，或通過訪問Biomea網站的投資者與媒體部分進行訪問。網絡廣播的重播將在現場演講後提供。
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
關於Biomea Fusion
Biomea Fusion是一家臨牀階段生物製藥公司，專注於發現和開發口服共價小分子，以改善糖尿病、肥胖和遺傳性癌症患者的生活。共價小分子是一種合成化合物，可以與其靶蛋白形成永久性結合，並比傳統的非共價藥物提供許多潛在優勢，包括更高的靶向選擇性、更低的藥物暴露，以及更深入、更持久的反應能力。
We are utilizing our proprietary FUSION System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to significantly improve disease treatments for the patients we serve. We aim to cure.
我們正在利用我們專有的FUSION系統發現、設計和開發下一代共價結合小分子藥物，旨在爲患者最大化臨牀收益。我們旨在顯著改善我們服務的患者的疾病治療，力求治癒。
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
請訪問我們的官方網站 biomeafusion.com，並關注我們 LinkedIn, X 和 臉書.
Contact:
Ramses Erdtmann
COO & President of Biomea Fusion
re@biomeafusion.com
聯繫:
拉美西斯·厄爾特曼
Biomea Fusion 的首席運營官兼總裁
re@biomeafusion.com
譯文內容由第三人軟體翻譯。